2019 IASLC Best of the World Lung Cancer Conference Results in New Virtual Collaboration
Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that […] Read more
Checkpoint Inhibitors and Clinical Decision Making: A Q&A with Dr. Nasser H. Hanna
Posted: May 27, 2019 Nasser H. Hanna, MD, is the Tom and Julie Wood Family Foundation Professor of Lung Cancer Clinical Research at Indiana University School of Medicine, and he specializes […] Read more
By Alice Shaw, MD, PhD Posted: May 27, 2019 On November 2, 2018, lorlatinib, a potent and central nervous system (CNS)–penetrant next-generation ALK/ROS1 inhibitor, was granted accelerated approval by the U.S. […] Read more
By Anne-Claire Toffart, MD, PhD, and Jean-François Timsit, MD, PhD Posted: April 1, 2019 Dr. Anne-Claire Toffart Survival rates for patients with lung cancer who were admitted into the intensive care […] Read more
Point/Counterpoint: Why TMB Should or Should Not Be Assessed in Patients with Advanced NSCLC
Posted: April 1, 2019 Why TMB Should Be Assessed in Patients with Advanced NSCLC By Fabrice Barlesi, MD, PhD Dr. Fabrice Barlesi Immune checkpoint inhibitors, especially PD-1 and PD-L1 inhibitors, have […] Read more
Understanding the Effects of Time to Surgery on Upstaging for Stage I Non-Small Cell Lung Cancer
By Russell Bahar, Bsc and Elliot Wakeam, MD, MPH Posted: April 1, 2019 IN REFERENCE TO: Serna-Gallegos DR, et al Effects of time from completed clinical staging to surgery: Does it […] Read more
Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer
By Michael MacManus, MD, FRANZCR, and Tim Akhurst, MD, FRACP Posted: March 1, 2019 Dr. Michael MacManus 18F-FDG PET/CT scans portray living biology and are indispensable in thoracic oncologic evaluations, […] Read more
The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management
By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease […] Read more
By Anne-Marie C. Dingemans, MD, PhD, and Lizza E.L. Hendriks, MD, PhD Posted: October 2018 Patients with stage IV NSCLC are generally viewed as having incurable disease; however, for years, […] Read more
By Edgardo S. Santos Castillero, MD, FACP Posted: October 2018 The approval of osimertinib in the frontline setting for patients with EGFR-sensitizing mutations has immediately challenged the decision-making process for […] Read more